ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis

Company Overview

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

Key Stats

• Today's Range: $1.08 to $1.33
• 50-Day Range: $1.00 to $2.54
• 52-Week Range: $0.98 to $25.00
• Volume: 270,292 shs
• Average Volume: 489,101 shs
• Market Capitalization: $2.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $120.00
• Consensus Rating: Buy

ZyVersa Therapeutics Stock Analysis - MarketRank™

ZyVersa Therapeutics scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ZyVersa Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ZyVersa Therapeutics are expected to decrease in the coming year, from ($22.70) to ($46.10) per share.

Price to Book Value per Share Ratio

ZyVersa Therapeutics has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.68% of the float of ZyVersa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ZyVersa Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ZyVersa Therapeutics has recently increased by 34.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ZyVersa Therapeutics does not currently pay a dividend.

Dividend Growth

ZyVersa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.68% of the float of ZyVersa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ZyVersa Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ZyVersa Therapeutics has recently increased by 34.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for ZyVersa Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.59% of the stock of ZyVersa Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.91% of the stock of ZyVersa Therapeutics is held by institutions.

ZVSA Stock Analysis - Frequently Asked Questions

How have ZVSA shares performed this year?

ZyVersa Therapeutics' stock was trading at $9.00 on January 1st, 2024. Since then, ZVSA stock has decreased by 87.3% and is now trading at $1.14.
View the best growth stocks for 2024 here.

How were ZyVersa Therapeutics' earnings last quarter?

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) released its earnings results on Friday, August, 9th. The company reported ($3.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.20) by $1.89.

When did ZyVersa Therapeutics' stock split?

ZyVersa Therapeutics's stock reverse split on Friday, April 26th 2024. The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of ZyVersa Therapeutics?

Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ZyVersa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZyVersa Therapeutics investors own include Tesla (TSLA), Lucid Group (LCID), NVIDIA (NVDA), XPeng (XPEV), Akebia Therapeutics (AKBA), JPMorgan Chase & Co. (JPM) and Eli Lilly and Company (LLY).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZVSA
• CUSIP: N/A
• CIK: 1859007
• Web: www.zyversa.com
• Phone: 754-231-1688
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $120.00
• High Stock Price Target: $120.00
• Low Stock Price Target: $120.00
• Potential Upside/Downside: +10,426.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -224.85%
• Return on Assets: -103.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $88.98 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 2,340,000
• Free Float: 2,330,000
• Market Cap: $2.67 million
• Optionable: Not Optionable
• Beta: 0.45